BeStock  
Stocks › Biotechnology › EXEL

Exelixis EXEL

US equityMarket cap rank #1070Biotechnology
$64.63 −$1.20 (-1.82%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $64.63 0.00%
Open$65.95
Prev close$65.83
Day range$64.45 – $66.94
Volume2.19M
Market cap$15.77B
P/E (TTM)19.4
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$658.70M+10.2% YoY
Operating profit$268.42M+4.7% YoY
Net profit$218.10M+12.7% YoY
Diluted EPS$0.85+23.2% YoY
Free cash flow$269.89M-4.8% YoY
Operating cash flow$279.96M

Revenue, last 8 quarters

$566.8MDec '24$555.4MMar '25$568.3MJun '25$597.8MSep '25$598.7MDec '25$610.8MMar '26$628.7MJun '26$658.7MSep '26

Net profit, last 8 quarters

$139.9MDec '24$159.6MMar '25$184.8MJun '25$193.6MSep '25$244.5MDec '25$210.5MMar '26$212.1MJun '26$218.1MSep '26

Diluted EPS by quarter

0.48Dec '240.55Mar '250.65Jun '250.69Sep '250.88Dec '250.79Mar '260.82Jun '260.85Sep '26

Free cash flow by quarter

$226.3MDec '24$189.0MMar '25$45.4MJun '25$283.6MSep '25$326.4MDec '25$249.8MMar '26$298.4MJun '26$269.9MSep '26

Annual revenue

$987.5MFY20$1.4BFY21$1.6BFY22$1.8BFY23$2.2BFY24$2.3BFY25

Profitability & balance sheet

Gross margin96.3%
Operating margin40.2%
Net margin35.5%
Return on equity44.3%
Return on assets33.2%
Return on invested capital38.5%
Current ratio3.21
Liabilities / assets27.0%
Cash & investments$892.02M
Total debt$162.20M
Net cash (debt)$729.82M
Free cash flow / sales45.8%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • CABOMETYX$603.15M 90.9%
  • License revenues$58.41M 8.8%
  • COMETRIQ$1.77M 0.3%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $658.70M $628.69M $610.81M $2.32B $598.66M
Total Operating Revenue $658.70M $628.69M $610.81M $2.32B $598.66M
Cost of Revenue $26.23M $20.66M $19.95M $83.70M $26.48M
Gross Profit $632.46M $608.03M $590.86M $2.24B $572.18M
Operating Expense $364.04M $359.62M $339.52M $1.34B $336.27M
Selling and Admin Expenses $154.56M $147.63M $139.60M $518.73M $123.02M
-General & Admin Expense $154.56M $147.63M $139.60M $518.73M $123.02M
Research & Development $209.48M $211.99M $199.92M $825.00M $213.25M
Operating Profit $268.42M $248.41M $251.34M $892.70M $235.91M
Net Non-Operating Interest Income (Expense) $14.32M $14.21M $16.13M $69.21M $17.43M
Non-Operating Interest Income $14.32M $14.21M $16.13M $69.21M $17.43M
Other Income (Expense) $47,000.00 $54,000.00 $219,000.00 -$20.71M -$648,000.00
Special Income (Charges) $0.00 – – -$20.51M -$694,000.00
-Less:Restructuring and Mergern & Acquisition $0.00 – – $20.51M $694,000.00
Other Non-Operating Income (Expenses) $47,000.00 $54,000.00 $219,000.00 -$198,000.00 $46,000.00
Pretax Profit $282.79M $262.68M $267.69M $941.21M $252.69M
Tax $64.69M $50.63M $57.22M $158.64M $8.16M
Net Profit $218.10M $212.05M $210.47M $782.57M $244.53M
Profit from Continuing Operations $218.10M $212.05M $210.47M $782.57M $244.53M
Net Income to Parent Company $218.10M $212.05M $210.47M $782.57M $244.53M
Net Income to Common Stockholders $218.10M $212.05M $210.47M $782.57M $244.53M
Basic EPS $0.88 $0.85 $0.81 $2.88 $0.92
Diluted EPS $0.85 $0.82 $0.79 $2.78 $0.88
-Less:Impairment of Capital Assets – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $2.51B $2.49B $2.59B $2.84B $2.84B
Total Current Assets $1.32B $1.25B $1.21B $1.44B $1.44B
Cash and Cash Equivalents & Short-Term Investments $892.02M $839.39M $777.21M $1.06B $1.06B
-Cash and Cash Equivalents $304.77M $281.45M $226.15M $482.49M $482.49M
-Short Term Investments $587.24M $557.94M $551.06M $576.60M $576.60M
Receivables $328.47M $322.21M $328.95M $286.92M $286.92M
-Accounts Receivable $328.47M $322.21M $328.95M $286.92M $286.92M
Inventory $29.87M $28.73M $26.61M $21.69M $21.69M
Other Current Assets $71.27M $60.50M $75.88M $75.60M $75.60M
Total Non-Current Assets $1.19B $1.24B $1.38B $1.40B $1.40B
Net PPE $324.86M $340.59M $378.40M $441.27M $441.27M
-Gross PPE $324.86M $340.59M $378.40M $573.49M $573.49M
Investments and Advances $507.76M $544.93M $649.14M $603.60M $603.60M
Goodwill and Other Intangible Assets $63.68M $63.68M $63.68M $63.68M $63.68M
-Goodwill $63.68M $63.68M $63.68M $63.68M $63.68M
Non-Current Deferred Assets $295.56M $294.21M $293.73M $292.58M $292.58M
Total Liabilities $679.66M $650.47M $657.85M $683.10M $683.10M
Total Current Liabilities $411.88M $361.93M $370.98M $405.64M $405.64M
Payables $30.83M $39.06M $24.15M $29.62M $29.62M
-Accounts Payable $30.83M $39.06M $24.15M $29.62M $29.62M
Current Accrued Expenses $94.94M $84.86M $93.13M $88.53M $88.53M
Current Provisions $70.77M $66.71M $65.89M $59.90M $59.90M
Other Current Liabilities $114.84M $102.66M $100.29M $125.38M $125.38M
Total Non-Current Liabilities $267.78M $288.55M $286.87M $277.46M $277.46M
Long Term Debt and Capital Lease Obligation $162.20M $165.93M $169.54M $173.04M $173.04M
-Long Term Capital Lease Obligation $162.20M $165.93M $169.54M $173.04M $173.04M
Other Non-Current Liabilities $105.58M $122.62M $117.33M $104.42M $104.42M
Total Equity $1.83B $1.84B $1.94B $2.16B $2.16B
Stockholders' Equity $1.83B $1.84B $1.94B $2.16B $2.16B
Capital Stock $245,000.00 $249,000.00 $254,000.00 $262,000.00 $262,000.00
-Common Stock $245,000.00 $249,000.00 $254,000.00 $262,000.00 $262,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $2.10B $2.11B $2.15B $2.23B $2.23B
Retained Earnings -$258.80M -$262.53M -$215.79M -$76.83M -$76.83M
Gains/Losses Not Affecting Retained Earnings -$6.59M -$2.01M -$415,000.00 $3.48M $3.48M
-Available for Sale Securities – $544.93M $649.14M – –
-Accumulated Depreciation – – – -$132.23M -$132.23M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $279.96M $307.74M $251.85M $884.27M $333.52M
Net cash flow from continuing operations $279.96M $307.74M $251.85M $884.27M $333.52M
Net Income from Continuing Operations $218.10M $212.05M $210.47M $782.57M $244.53M
Depreciation & Depletion & Amortization $6.94M $6.98M $6.95M $29.06M $6.95M
Other Non-Cash Items $5.63M $13.23M $6.00M $24.62M $8.67M
Change in Working Capital $20.58M $42.92M -$620,000.00 -$191.20M -$72.96M
-Change in Receivables -$6.25M $6.73M -$42.03M -$21.40M $22.81M
-Change in Inventory -$320,000.00 -$44,000.00 -$3.39M $12.23M $13.81M
-Change in Prepaid Assets -$4.81M $40.50M $58.65M -$133.77M -$97.03M
-Change in Payables and Accrued Expense $31.96M -$4.28M -$13.85M -$48.25M -$12.55M
Net cash flow from investing -$6.71M $91.43M -$51.07M $350.44M $27.24M
Net Cash Flow from Continuing Investing Activities -$6.71M $91.43M -$51.07M $350.44M $27.24M
Net PPE Purchase and Sale -$2.49M -$6.82M -$1.51M -$8.43M -$1.16M
Net Intangibles Purchase and Sale -$7.58M -$2.50M -$525,000.00 -$31.50M -$6.00M
Net Investment Purchase and Sale $3.36M $100.75M -$49.04M $390.37M $34.40M
Financing Cash Flow -$249.92M -$343.88M -$457.11M -$969.59M -$254.57M
Net Cash Flow from Continuing Financing Activities -$249.92M -$343.88M -$457.11M -$969.59M -$254.57M
Net Common Stock Issuance -$249.96M -$322.97M -$430.35M -$947.51M -$257.62M
Proceeds from Stock Option Exercised $3.40M $15.44M $7.47M $49.14M $7.88M
Net Other Financing Charges -$3.36M -$36.34M -$34.23M -$71.22M -$4.83M
Ending Cash Balance $304.77M $281.45M $226.15M $482.49M $482.49M
Net Change in Cash $23.33M $55.30M -$256.34M $265.11M $106.19M
Beginning Cash Balance $281.45M $226.15M $482.49M $217.37M $376.30M
Free Cash Flow $269.89M $298.43M $249.81M $844.34M $326.36M
Deferred Tax – – – $126.24M –

Discussion

No comments yet — be the first to weigh in on EXEL.

Sign in to join the discussion.

Scroll to Top